Nanoliposomes Reduce Stroke Injury Following Middle Cerebral Artery Occlusion in Mice.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
02 2022
Historique:
pubmed: 9 11 2021
medline: 19 2 2022
entrez: 8 11 2021
Statut: ppublish

Résumé

Neuroprotective strategies for stroke remain inadequate. Nanoliposomes comprised of phosphatidylcholine, cholesterol, and monosialogangliosides (nanoliposomes) induced an antioxidant protective response in endothelial cells exposed to amyloid insults. We tested the hypotheses that nanoliposomes will preserve human neuroblastoma (SH-SY5Y) and human brain microvascular endothelial cells viability following oxygen-glucose deprivation (OGD)-reoxygenation and will reduce injury in mice following middle cerebral artery occlusion. SH-SY5Y and human brain microvascular endothelial cells were exposed to oxygen-glucose deprivation-reoxygenation (3 hours 0.5%-1% oxygen and glucose-free media followed by 20-hour ambient air/regular media) without or with nanoliposomes (300 µg/mL). Viability was measured (calcein-acetoxymethyl fluorescence) and protein expression of antioxidant proteins HO-1 (heme oxygenase-1), NQO1 (NAD[P]H quinone dehydrogenase 1), and SOD1 (superoxide dismutase 1) were measured by Western blot. C57BL/6J mice were treated with saline (n=8) or nanoliposomes (10 mg/mL lipid, 200 µL, n=7) while undergoing 60-minute middle cerebral artery occlusion followed by reperfusion. Day 2 postinjury neurological impairment score and infarction size were compared. SH-SY5Y and human brain microvascular endothelial cells showed reduced viability post-oxygen-glucose deprivation-reoxygenation that was reversed by nanoliposomes. Nanoliposomes increased protein expressions of HO-1, NQO1 in both cell types and SOD1 in human brain microvascular endothelial cells. Nanoliposomes-treated mice showed reduced neurological impairment and brain infarct size (18.8±2% versus 27.3±2.3%, Nanoliposomes reduced stroke injury in mice subjected to middle cerebral artery occlusion likely through induction of an antioxidant protective response. Nanoliposome is a candidate novel agent for stroke.

Sections du résumé

BACKGROUND AND PURPOSE
Neuroprotective strategies for stroke remain inadequate. Nanoliposomes comprised of phosphatidylcholine, cholesterol, and monosialogangliosides (nanoliposomes) induced an antioxidant protective response in endothelial cells exposed to amyloid insults. We tested the hypotheses that nanoliposomes will preserve human neuroblastoma (SH-SY5Y) and human brain microvascular endothelial cells viability following oxygen-glucose deprivation (OGD)-reoxygenation and will reduce injury in mice following middle cerebral artery occlusion.
METHODS
SH-SY5Y and human brain microvascular endothelial cells were exposed to oxygen-glucose deprivation-reoxygenation (3 hours 0.5%-1% oxygen and glucose-free media followed by 20-hour ambient air/regular media) without or with nanoliposomes (300 µg/mL). Viability was measured (calcein-acetoxymethyl fluorescence) and protein expression of antioxidant proteins HO-1 (heme oxygenase-1), NQO1 (NAD[P]H quinone dehydrogenase 1), and SOD1 (superoxide dismutase 1) were measured by Western blot. C57BL/6J mice were treated with saline (n=8) or nanoliposomes (10 mg/mL lipid, 200 µL, n=7) while undergoing 60-minute middle cerebral artery occlusion followed by reperfusion. Day 2 postinjury neurological impairment score and infarction size were compared.
RESULTS
SH-SY5Y and human brain microvascular endothelial cells showed reduced viability post-oxygen-glucose deprivation-reoxygenation that was reversed by nanoliposomes. Nanoliposomes increased protein expressions of HO-1, NQO1 in both cell types and SOD1 in human brain microvascular endothelial cells. Nanoliposomes-treated mice showed reduced neurological impairment and brain infarct size (18.8±2% versus 27.3±2.3%,
CONCLUSIONS
Nanoliposomes reduced stroke injury in mice subjected to middle cerebral artery occlusion likely through induction of an antioxidant protective response. Nanoliposome is a candidate novel agent for stroke.

Identifiants

pubmed: 34743535
doi: 10.1161/STROKEAHA.121.037120
doi:

Substances chimiques

Antioxidants 0
Liposomes 0
Membrane Proteins 0
Neuroprotective Agents 0
Heme Oxygenase-1 EC 1.14.14.18
Hmox1 protein, mouse EC 1.14.14.18
Sod1 protein, mouse EC 1.15.1.1
Superoxide Dismutase-1 EC 1.15.1.1
NAD(P)H Dehydrogenase (Quinone) EC 1.6.5.2
Nqo1 protein, mouse EC 1.6.5.2
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e37-e41

Subventions

Organisme : BLRD VA
ID : I01 BX003767
Pays : United States
Organisme : RRD VA
ID : I01 RX002691
Pays : United States

Auteurs

Saif Ahmad (S)

Barrow Neurological Institute, Phoenix, AZ (S.A., A.K., A.F.D.).
Phoenix Veterans Affairs Healthcare System, AZ (S.A., S.T., N.K., D.R.G., J.L., R.Q.M.).

Seth Truran (S)

Phoenix Veterans Affairs Healthcare System, AZ (S.A., S.T., N.K., D.R.G., J.L., R.Q.M.).

Nina Karamanova (N)

Phoenix Veterans Affairs Healthcare System, AZ (S.A., S.T., N.K., D.R.G., J.L., R.Q.M.).

Adam Kindelin (A)

Barrow Neurological Institute, Phoenix, AZ (S.A., A.K., A.F.D.).

Maria Lozoya (M)

Midwestern University, Glendale, AZ (M.L., V.W.).

Volkmar Weissig (V)

Midwestern University, Glendale, AZ (M.L., V.W.).

Hannah Emerson (H)

Barrow Neurological Institute, Phoenix, AZ (S.A., A.K., A.F.D.).

Daniel R Griffiths (DR)

Phoenix Veterans Affairs Healthcare System, AZ (S.A., S.T., N.K., D.R.G., J.L., R.Q.M.).
University of Arizona College of Medicine-Phoenix (D.R.G., T.V., J.L., A.F.D., R.Q.M.).

Tyler Vail (T)

University of Arizona College of Medicine-Phoenix (D.R.G., T.V., J.L., A.F.D., R.Q.M.).

Jonathan Lifshitz (J)

Phoenix Veterans Affairs Healthcare System, AZ (S.A., S.T., N.K., D.R.G., J.L., R.Q.M.).
University of Arizona College of Medicine-Phoenix (D.R.G., T.V., J.L., A.F.D., R.Q.M.).

Andrew F Ducruet (AF)

University of Arizona College of Medicine-Phoenix (D.R.G., T.V., J.L., A.F.D., R.Q.M.).

Raymond Q Migrino (RQ)

Phoenix Veterans Affairs Healthcare System, AZ (S.A., S.T., N.K., D.R.G., J.L., R.Q.M.).
University of Arizona College of Medicine-Phoenix (D.R.G., T.V., J.L., A.F.D., R.Q.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH